Partnering opportunities

EDO has demonstrated the ability to move optimised candidates with initial proof of activity to investigational new drug status in just two years, significantly improving typical pharmaceutical development timelines and costs and has successfully moved the investigational new drug EDO-S101 (tinostamustine) through preclinical safety testing and into the human study phase.

EDO conducts research with leading academic researchers and clinical specialists worldwide. If you have a potential partnering opportunity or are interested in finding out more, please contact:

Click a logo to see more information.

Kinesis logo
Makara Health logo
Mundipharma logo
Northlake crystal logo
Purdue logo
Celonic - beyond biomanfacturing
Fusion Antibodies - from genes to protein to antibodies